The University of Southampton
University of Southampton Institutional Repository

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials
Background: it is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago–gastric junction (OGJ) versus gastric adenocarcinoma].
Patients and methods: a total of 2110 patients were enrolled in four randomised controlled trials (RCTs) assessing fluoropyrimidine ± platinum-based chemotherapy. This analysis used individual patient data and restricted to patients with adenocarcinoma who received one or more dose of chemotherapy. Gastric origin was the control in comparisons of tumour origin.
Results: of the 2110 patients randomised, 1775 (84%) patients had adenocarcinoma with oesophageal (n?=?485), OGJ (n?=?457) and gastric (n?=?833) origins. The median OS was 9.5 months in oesophageal, 9.3 months in OGJ and 8.7 months in gastric cancer (P?=?0.68). RR was 44.1% in oesophageal, 41.1% in OGJ and 35.6% in gastric cancers (P?=?0.11 and 0.27, respectively, compared with gastric cancer on multivariate analysis). Toxicity composite end point occurred in 46%, 47% and 45% in oesophageal, OGJ and gastric cancers, respectively (P?=?0.85 and 0.62 compared with gastric).
Conclusions: in our large multicentre RCT dataset, no significant differences were demonstrated on multivariate analyses in OS, RR and toxic effects among patients with advanced oesophageal, OGJ and gastric adenocarcinoma. Future RCTs should not exclude oesophageal adenocarcinoma
gastric adenocarcinoma, oesophagus, oesophago-gastric junction
0923-7534
885-891
Chau, I.
ff7dfc68-c4ae-4fb9-b035-8b646d32e451
Norman, A.R.
9d5636c7-72da-4a29-80f1-e3d79c501639
Cunningham, D.
02b4fd3a-f452-4419-96a7-f98f609f098d
Oates, J.
813bc998-fd2e-4f29-bae2-8881beabba0e
Hawkins, R.
359a61bf-7393-4b1d-a1c1-cecc85ee8107
Iveson, T.
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
Nicolson, M.
293bfbb1-f76e-408e-a6e3-615dffb59acd
Harper, P.
93a9f992-d1de-4748-b77a-00917cf3e879
Seymour, M.
79cb91bf-b3e6-4222-82cf-c0072be29613
Hickish, T.
d17bf903-3f13-4b46-9389-f0f458083442
Chau, I.
ff7dfc68-c4ae-4fb9-b035-8b646d32e451
Norman, A.R.
9d5636c7-72da-4a29-80f1-e3d79c501639
Cunningham, D.
02b4fd3a-f452-4419-96a7-f98f609f098d
Oates, J.
813bc998-fd2e-4f29-bae2-8881beabba0e
Hawkins, R.
359a61bf-7393-4b1d-a1c1-cecc85ee8107
Iveson, T.
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
Nicolson, M.
293bfbb1-f76e-408e-a6e3-615dffb59acd
Harper, P.
93a9f992-d1de-4748-b77a-00917cf3e879
Seymour, M.
79cb91bf-b3e6-4222-82cf-c0072be29613
Hickish, T.
d17bf903-3f13-4b46-9389-f0f458083442

Chau, I., Norman, A.R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M. and Hickish, T. (2009) The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology, 20 (5), 885-891. (doi:10.1093/annonc/mdn716).

Record type: Article

Abstract

Background: it is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago–gastric junction (OGJ) versus gastric adenocarcinoma].
Patients and methods: a total of 2110 patients were enrolled in four randomised controlled trials (RCTs) assessing fluoropyrimidine ± platinum-based chemotherapy. This analysis used individual patient data and restricted to patients with adenocarcinoma who received one or more dose of chemotherapy. Gastric origin was the control in comparisons of tumour origin.
Results: of the 2110 patients randomised, 1775 (84%) patients had adenocarcinoma with oesophageal (n?=?485), OGJ (n?=?457) and gastric (n?=?833) origins. The median OS was 9.5 months in oesophageal, 9.3 months in OGJ and 8.7 months in gastric cancer (P?=?0.68). RR was 44.1% in oesophageal, 41.1% in OGJ and 35.6% in gastric cancers (P?=?0.11 and 0.27, respectively, compared with gastric cancer on multivariate analysis). Toxicity composite end point occurred in 46%, 47% and 45% in oesophageal, OGJ and gastric cancers, respectively (P?=?0.85 and 0.62 compared with gastric).
Conclusions: in our large multicentre RCT dataset, no significant differences were demonstrated on multivariate analyses in OS, RR and toxic effects among patients with advanced oesophageal, OGJ and gastric adenocarcinoma. Future RCTs should not exclude oesophageal adenocarcinoma

This record has no associated files available for download.

More information

Published date: May 2009
Keywords: gastric adenocarcinoma, oesophagus, oesophago-gastric junction
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 79354
URI: http://eprints.soton.ac.uk/id/eprint/79354
ISSN: 0923-7534
PURE UUID: bf22e943-471c-44f8-b3fa-4a748df979bb
ORCID for T. Iveson: ORCID iD orcid.org/0000-0002-4681-2712

Catalogue record

Date deposited: 15 Mar 2010
Last modified: 14 Mar 2024 02:41

Export record

Altmetrics

Contributors

Author: I. Chau
Author: A.R. Norman
Author: D. Cunningham
Author: J. Oates
Author: R. Hawkins
Author: T. Iveson ORCID iD
Author: M. Nicolson
Author: P. Harper
Author: M. Seymour
Author: T. Hickish

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×